By Chris Wack

Beam Therapeutics Inc. said Friday that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.

The biotechnology company said its BEAM-201 is a specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate.

"The FDA's clearance of our IND for BEAM-201 is an exciting moment for Beam and for the field of gene editing, as it represents the first IND clearance for a multiplex-base edited investigational drug," said John Evans, chief executive of Beam.

Beam shares were up 11% to $51 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

December 02, 2022 06:55 ET (11:55 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Mar 2023 to Mar 2023 Click Here for more Beam Therapeutics Charts.
Beam Therapeutics (NASDAQ:BEAM)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Beam Therapeutics Charts.